UAM | UAM_Biblioteca | Unified search engine | Scientific Production Portal | UAM Research Data Repository
Biblos-e Archivo
    • español
    • English
  • English 
    • español
    • English
  • Log in
JavaScript is disabled for your browser. Some features of this site may not work without it.

Search Biblos-e Archivo

Advanced Search

Browse

All of Biblos-e ArchivoCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsFacultiesThis CollectionBy Issue DateAuthorsTitlesSubjectsFaculties

My Account

Log inRegister

Statistics

View Usage Statistics

Help

Information about Biblos-e ArchivoI want to submit my workFrequently Asked Questions

UAM_Biblioteca

View Item 
  •   Biblos-e Archivo
  • 1 - Producción científica en acceso abierto de la UAM
  • Producción científica en acceso abierto de la UAM
  • View Item
  •   Biblos-e Archivo
  • 1 - Producción científica en acceso abierto de la UAM
  • Producción científica en acceso abierto de la UAM
  • View Item

GMP-compliant manufacturing of NKG2D CAR Memory T cells using CliniMACS prodigy

Author
Fernández, Lucía; Fernández, Adrián; Mirones, Isabel; Escudero, Adela; Cardoso, Leila; Vela, María; Lanzarot, Diego; Paz, Raquel de; Leivas, Alejandra; Gallardo, Miguel; Marcos, Antonio; Romero, Ana Belén; Martínez-López, Joaquín; Pérez Martínez, Antoniountranslated
Entity
UAM. Departamento de Pediatría; Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)
Publisher
Frontiers Media
Date
2019-10-10
Citation
10.3389/fimmu.2019.02361
Frontiers in Immunology 10.October (2019): 2361
 
 
 
ISSN
1664-3224
DOI
10.3389/fimmu.2019.02361
Funded by
This study was funded in part by the National Health Service of Spain, Instituto de Salud Carlos III (ISCIII), FONDOS FEDER grant (FIS) PI18/01301, by the Unoentrecienmil Foundation and by CRIS Cancer Foundation to beat Cancer (http://criscancer. org). LF, AF, IM, and AE are granted by CRIS Cancer Foundation to beat cancer
Project
Gobierno de España. PI18/01301
Editor's Version
https://doi.org/10.3389/fimmu.2019.02361
Subjects
NKG2D CAR; Memory T cells; Automated production; Large-scale; Clinical-grade; CliniMACS prodigy; Medicina
URI
http://hdl.handle.net/10486/691848
Rights
© 2019 Fernández, Fernández, Mirones, Escudero, Cardoso, Vela, Lanzarot, de Paz, Leivas, Gallardo, Marcos, Romero, Martínez-López and Pérez- Martínez.

Licencia Creative Commons
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.

Abstract

Natural killer group 2D (NKG2D) is a natural killer (NK) cell-activating receptor that recognizes different stress-induced ligands that are overexpressed in a variety of childhood and adult tumors. NKG2D chimeric antigen receptor (CAR) T cells have shown potent anticancer effects against different cancer types. A second-generation NKG2D CAR was generated by fusing full-length human NKG2D to 4-1BB costimulatory molecule and CD3z signaling domain. Patient-derived CAR T cells show limitations including inability to manufacture CAR T cells from the patients’ own T cells, disease progression, and death prior to return of engineered cells. The use of allogeneic T cells for CAR therapy could be an attractive alternative, although undesirable graft vs. host reactions may occur. To avoid such adverse effects, we used CD45RA− memory T cells, a T-cell subset with less alloreactivity, as effector cells to express NKG2D CAR. In this study, we developed a protocol to obtain large-scale NKG2D CAR memory T cells for clinical use by using CliniMACS Prodigy, an automated closed system compliant with Good Manufacturing Practice (GMP) guidelines. CD45RA+ fraction was depleted from healthy donors’ non-mobilized apheresis using CliniMACS CD45RA Reagent and CliniMACS Plus device. A total of 108 CD45RA− cells were cultured in TexMACS media supplemented with 100 IU/mL IL-2 and activated at day 0 with T Cell TransAct. Then, we used NKG2D-CD8TM-4-1BB-CD3z lentiviral vector for cell transduction (MOI = 2). NKG2D CAR T cells expanded between 10 and 13 days. Final cell products were analyzed to comply with the specifications derived from the quality and complementary controls carried out in accordance with the instructions of the Spanish Regulatory Agency ofMedicines andMedical Devices (AEMPS) for themanufacture of investigational advanced therapy medicinal products (ATMPs). We performed four validations. The manufacturing protocol here described achieved large numbers of viable NKG2D CAR memory T cells with elevated levels of NKG2D CAR expression and highly cytotoxic against Jurkat and 531MII tumor target cells. CAR T cell final products met release criteria, except for one showing myc overexpression and another with viral copy number higher than five. Manufacturing of clinical-grade NKG2D CAR memory T cells using CliniMACS Prodigy is feasible and reproducible, widening clinical application of CAR T cell therapies
Show full item record

Files in this item

Thumbnail
Name
GMP_fernandez_FI_2019.pdf
Size
894.3Kb
Format
PDF

Refworks Export

Google™ Scholar:Fernández, Lucía - Fernández, Adrián - Mirones, Isabel - Escudero, Adela - Cardoso, Leila - Vela, María - Lanzarot, Diego - Paz, Raquel de - Leivas, Alejandra - Gallardo, Miguel - Marcos, Antonio - Romero, Ana Belén - Martínez-López, Joaquín - Pérez Martínez, Antonio

This item appears in the following Collection(s)

  • Producción científica en acceso abierto de la UAM [16545]

Related items

Showing items related by title, author, creator and subject.

  • Optimizing the procedure to manufacture clinical‐grade NK cells for adoptive immunotherapy 

    Fernández, Adrián; Escudero, Adela; Matamala, Nerea; Mirones, Isabel; Pernas, Alicia; Cobo, Marta; Casado, Gema; Lanzarot, Diego; Vela, María; Ferreras, Cristina; Mestre, Carmen; Viejo, Aurora; Leivas, Alejandra; Martínez, Joaquín; Fernández, Lucía; Navarro‐Zapata, Alfonso; Ruz‐Caracuel, Beatriz; Rodríguez‐Antolín, Carlos; Pérez‐Martínez, Antonio
    2021-02-02
  • Optimizing the procedure to manufacture clinical‐grade NK cells for adoptive immunotherapy 

    Fernández, Adrián; Navarro‐zapata, Alfonso; Escudero, Adela; Matamala, Nerea; Ruz‐caracuel, Beatriz; Mirones, Isabel; Pernas, Alicia; Cobo, Marta; Casado, Gema; Lanzarot, Diego; Rodríguez‐antolín, Carlos; Vela, María; Ferreras, Cristina; Mestre, Carmen; Viejo, Aurora; Leivas, Alejandra; Martínez, Joaquín; Fernández, Lucía; Pérez Martínez, AntonioAutoridad UAM
    2021-02-02
  • NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma 

    Leivas, Alejandra; Valeri, Antonio; Córdoba, Laura; García-Ortiz, Almudena; Ortiz, Alejandra; Sánchez-Vega, Laura; Graña-Castro, Osvaldo; Fernández, Lucía; Carreño-Tarragona, Gonzalo; Pérez, Manuel; Megías, Diego; Paciello, María Liz; Sánchez-Pina, Jose; Pérez Martínez, AntonioAutoridad UAM; Lee, Dean A.; Powell, Daniel J.; Río, Paula; Martínez-López, Joaquín
    2021-08-14
All the documents from Biblos-e Archivo are protected by copyrights. Some rights reserved.
Universidad Autónoma de Madrid. Biblioteca
Contact Us | Send Feedback
We are onFacebookCanal BiblosYouTubeTwitterPinterestWhatsappInstagram
 

 

All the documents from Biblos-e Archivo are protected by copyrights. Some rights reserved.
Universidad Autónoma de Madrid. Biblioteca
Contact Us | Send Feedback
We are onFacebookCanal BiblosYouTubeTwitterPinterestWhatsappInstagram